Explore our SITC Presentations

photo courtesy Nasdaq, Inc.

About Us

MiNK Therapeutics is a clinical-stage precision oncology company developing allogeneic, invariant natural killer T cell therapies for cancer and other immune-mediated diseases. The lead product is an off-the-shelf, cell therapy based on a targeted platform of invariant natural killer T (iNKT) cells. iNKTs have a dual-mechanism of action with an internal targeting and homing device (iTCR) that modulates both arms of immunity, innate and adaptive. iNKTs combine the killing features of natural killer (NK) cells with the durable memory response of T cells. iNKT cells have been demonstrated to be highly effective in treating solid tumor cancers in their native form and MiNK has demonstrated that these cells can be further engineered or edited for super-targeting.

Executive Leadership

X

Scientific Advisory Board

Board of Directors

Management

Robert Stein, M.D., Ph.D.

Scientific Advisor

Robert Stein, M.D., Ph.D.
Scientific Advisor

Manuel Hidalgo, M.D., Ph.D.

Scientific Advisor

Manuel Hidalgo, M.D., Ph.D.
Scientific Advisor

Mark Exley, Ph.D.

Scientific Advisor

Mark Exley, Ph.D.
Scientific Advisor

Jenny Gumperz, Ph.D.

Scientific Advisor

Jenny Gumperz, Ph.D.
Scientific Advisor

Lydia Lynch, Ph.D.

Scientific Advisor

Lydia Lynch, Ph.D.
Scientific Advisor

Marcela Maus, M.D., Ph.D.

Scientific Advisor

Marcela Maus, M.D., Ph.D.
Scientific Advisor

Hagop Youssoufian, M.D.

Scientific Advisor

Hagop Youssoufian, M.D.
Scientific Advisor

Garo Armen, Ph.D.

Chairman

Garo Armen, Ph.D.
Chairman

John Baldoni, Ph.D.

Director

John Baldoni, Ph.D.
Director

Peter Behner

Director

Peter Behner
Director

Jennifer Buell, Ph.D.

President and CEO

Jennifer Buell, Ph.D.
President and CEO

Brian Corvese

Director

Brian Corvese
Director

Barbara Ryan

Director

Barbara Ryan
Director

Ulf Wiinberg

Director

Ulf Wiinberg
Director

Jennifer Buell, Ph.D.

President and CEO

Jennifer Buell, Ph.D.
President and CEO

Marc Van Dijk, Ph.D.

Chief Scientific Officer

Marc Van Dijk, Ph.D.
Chief Scientific Officer

Patrick Jordan, MBA

Vice President of Business Operations

Patrick Jordan, MBA
Vice President of Business Operations

Sonia De Munari, Ph.D., MBA

Head of Portfolio Strategy and Program Management

Sonia De Munari, Ph.D., MBA
Head of Portfolio Strategy and Program Management

Sandra Craig

Head of Manufacturing

Sandra Craig
Head of Manufacturing

Kimberly Ha

Head of Investor Relations

Kimberly Ha
Head of Investor Relations

Heather Boussios

General Counsel and Chief Compliance Officer

Heather Boussios
General Counsel and Chief Compliance Officer

Pipeline

MiNK's lead product candidate AGENT-797 is in multiple Phase 1 clinical trials with clinical and preclinical readouts anticipated later this year and in 2022. Our research team is focused on developing potential first-or best-in-class therapies using a next- generation technology platform to develop novel engineered iNKT cell therapies and bispecific iNKT cell engagers.

Target/Indication

Product

Pre-clinical

Early clinical

Next milestone

Native iNKT Cells

Oncology

Solid Tumors

AGENT-797 +/- Checkpoint Antibodies

Early clinical

2022
Phase 1 top-line readouts

r/r Multiple Myeloma

AGENT-797

Early clinical

2022
Phase 1 top-line readout

Immune-related diseases

GvHD

AGENT-797

Pre-clinical

2022
IND & phase 1 initiation

ARDS secondary to viral infections

AGENT-797

Early clinical

2022
Phase 1b data update

Targeted iNKT Cells

Oncology

BCMA-CAR-iNKT

Pre-clinical

2022
IND-Enabling

Stromal Target-CAR-iNKT

Pre-clinical

2022
IND-Enabling

NY-ESO-TCR

Pre-clinical

2022
IND-Ready*

iNKT Cell Engager

Pre-clinical

*Autologous T cell program IND-ready: allogeneic iNKT program in development